KR102914803B1 - 빈혈 치료에 있어서의 무스카린성 아세틸콜린 수용체 아형 4 길항제 - Google Patents

빈혈 치료에 있어서의 무스카린성 아세틸콜린 수용체 아형 4 길항제

Info

Publication number
KR102914803B1
KR102914803B1 KR1020217029823A KR20217029823A KR102914803B1 KR 102914803 B1 KR102914803 B1 KR 102914803B1 KR 1020217029823 A KR1020217029823 A KR 1020217029823A KR 20217029823 A KR20217029823 A KR 20217029823A KR 102914803 B1 KR102914803 B1 KR 102914803B1
Authority
KR
South Korea
Prior art keywords
delete delete
compound
bfu
formula
anemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217029823A
Other languages
English (en)
Korean (ko)
Other versions
KR20210144697A (ko
Inventor
요세프 알 아베드
링보 장
Original Assignee
콜드스프링하버러보러토리
더 파인스타인 인스티튜츠 포 메디칼 리서치
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 콜드스프링하버러보러토리, 더 파인스타인 인스티튜츠 포 메디칼 리서치 filed Critical 콜드스프링하버러보러토리
Publication of KR20210144697A publication Critical patent/KR20210144697A/ko
Application granted granted Critical
Publication of KR102914803B1 publication Critical patent/KR102914803B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217029823A 2019-03-25 2020-03-20 빈혈 치료에 있어서의 무스카린성 아세틸콜린 수용체 아형 4 길항제 Active KR102914803B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962823214P 2019-03-25 2019-03-25
US62/823,214 2019-03-25
PCT/US2020/023989 WO2020198054A1 (en) 2019-03-25 2020-03-20 Muscarinic acetylcholine receptor subtype 4 antagonists in the treatment of anemia

Publications (2)

Publication Number Publication Date
KR20210144697A KR20210144697A (ko) 2021-11-30
KR102914803B1 true KR102914803B1 (ko) 2026-01-20

Family

ID=72608578

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217029823A Active KR102914803B1 (ko) 2019-03-25 2020-03-20 빈혈 치료에 있어서의 무스카린성 아세틸콜린 수용체 아형 4 길항제

Country Status (12)

Country Link
US (1) US12497411B2 (cg-RX-API-DMAC7.html)
EP (1) EP3946321A4 (cg-RX-API-DMAC7.html)
JP (2) JP7558187B2 (cg-RX-API-DMAC7.html)
KR (1) KR102914803B1 (cg-RX-API-DMAC7.html)
CN (1) CN113613650B (cg-RX-API-DMAC7.html)
AU (1) AU2020247812B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021019189A2 (cg-RX-API-DMAC7.html)
CA (1) CA3132381A1 (cg-RX-API-DMAC7.html)
IL (1) IL286617A (cg-RX-API-DMAC7.html)
MX (1) MX2021011588A (cg-RX-API-DMAC7.html)
SG (1) SG11202109857UA (cg-RX-API-DMAC7.html)
WO (1) WO2020198054A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113613650B (zh) 2019-03-25 2024-12-10 冷泉港实验室 治疗贫血的毒蕈碱乙酰胆碱受体亚型4拮抗剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011113036A2 (en) 2010-03-12 2011-09-15 Whitehead Institute For Biomedical Research Compositions and methods for expanding bfu-e cells
WO2019010491A1 (en) 2017-07-07 2019-01-10 University Of Pittsburgh-Of The Commonwealth System Of Higher Education COMBINATIONS OF MEDICINES FOR THE PROTECTION AGAINST THE DEATH OF NEURONAL CELLS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3649626A (en) * 1970-04-27 1972-03-14 Warner Lambert Co Fused ring systems containing (1 3)oxazine
DK1282625T3 (da) * 2000-05-09 2004-11-15 Warner Lambert Co Anvendelsen af benzoxaziner i behandlingen af Parkinsons sygdom
CA2357306A1 (en) 2000-09-22 2002-03-22 Warner-Lambert Company Fused ring system containing indole as m4 selective aza-anthracene muscarinic receptor antagonists
US8329689B2 (en) * 2006-05-23 2012-12-11 Alexandre Vasilievich Ivachtchenko Substituted indoles and a method for the production and use thereof
EP3490542A4 (en) 2016-07-26 2020-07-08 Flagship Pioneering Innovations V, Inc. NEUROMODULATION COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATION OF AN ANTI-CANCER RESPONSE
CN113613650B (zh) 2019-03-25 2024-12-10 冷泉港实验室 治疗贫血的毒蕈碱乙酰胆碱受体亚型4拮抗剂

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011113036A2 (en) 2010-03-12 2011-09-15 Whitehead Institute For Biomedical Research Compositions and methods for expanding bfu-e cells
WO2019010491A1 (en) 2017-07-07 2019-01-10 University Of Pittsburgh-Of The Commonwealth System Of Higher Education COMBINATIONS OF MEDICINES FOR THE PROTECTION AGAINST THE DEATH OF NEURONAL CELLS

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Bioorganic and Medicinal Chemistry Letters, 1998, Vol. 8, No. 15, pp. 1991-1996*
Journal of Medicinal Chemistry, 2002, Vol. 45, No. 14, pp.3094-3102
Medicinal Chemistry Research, 2002, Vol. 11, No. 8, pp.423-433

Also Published As

Publication number Publication date
SG11202109857UA (en) 2021-10-28
IL286617A (en) 2021-10-31
CA3132381A1 (en) 2020-10-01
EP3946321A4 (en) 2023-03-08
JP2024102364A (ja) 2024-07-30
JP2022525293A (ja) 2022-05-12
MX2021011588A (es) 2021-12-15
CN113613650B (zh) 2024-12-10
AU2020247812B2 (en) 2025-09-11
BR112021019189A2 (pt) 2021-11-30
KR20210144697A (ko) 2021-11-30
AU2020247812A1 (en) 2021-09-30
JP7558187B2 (ja) 2024-09-30
US20220185821A1 (en) 2022-06-16
CN113613650A (zh) 2021-11-05
WO2020198054A1 (en) 2020-10-01
EP3946321A1 (en) 2022-02-09
US12497411B2 (en) 2025-12-16

Similar Documents

Publication Publication Date Title
EP2609082B1 (de) Imidazo[4,5-c]chinoline als dna-pk-inhibitoren
JP2021020957A (ja) 二官能性分子によって標的化タンパク質分解を誘導する方法
WO2023030685A1 (en) Novel ras inhibitors
JP2016014061A (ja) １，２−二置換複素環式化合物
EP2722332B1 (en) Quinolylpyrrolopyrimidyl fused-ring compound or salt thereof
EP3108883A1 (en) Therapeutic uses of non-peptide inhibitors of the calcineurin - nfat signalling pathway
KR102583817B1 (ko) 피롤로[1,2-b]피리다진 유도체
WO2020076738A2 (en) Protein-binding compounds
JP2022522942A (ja) 有機化合物
AU2018200421A1 (en) Naphthyridinedione derivatives
US20240252658A1 (en) Bifunctional protac-type compounds targeting pxr, method for preparing same and therapeutic use thereof
US20230055237A1 (en) Compounds and methods for the treatment of cystic fibrosis
KR102914803B1 (ko) 빈혈 치료에 있어서의 무스카린성 아세틸콜린 수용체 아형 4 길항제
EP4460492A1 (en) Compounds containing a hydroxyphenyl moiety and their use
Felicetti et al. New anti-ovarian cancer quinolone derivatives acting by modulating microRNA processing machinery
CN117916234A (zh) 作为tyk2/jak1假激酶结构域抑制剂的化合物及合成和使用方法
US12458637B2 (en) Targeting WNK1 in blood cancers
US11180475B2 (en) Crystal form I of a 5-aminopyrazole carboxamide compound as BTK inhibitor
CN110023298A (zh) 异柠檬酸脱氢酶(idh)抑制剂
JP2025533935A (ja) １－（スルホニル）－ｎ－フェニルピロリジン－２－カルボキサミド誘導体及びその使用
JP2016502531A (ja) ジヒドロ−ピリド−オキサジン誘導体の固体形態

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)